Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 million
read at Endpoints ↗DealNeutral
Leo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight.
Under the deal, Leo Pharma will provide up to $435 million in upfront and near‑term payments to secure the rights to the drug.
The agreement expands Leo Pharma's portfolio in rare disease therapeutics, but no further details on development timelines or commercial plans were disclosed.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure”
read at Endpoints ↗89 words · retrieved Aug 18
comments(0)
5-min edit window · permanent after that